Study S002764

A Multicenter, Randomized, Double-blind, Placebo-controlled Phase II Clinical Study to Evaluate the Efficacy and Safety of Subcutaneous Injection of DR10624 in Subjects With Severe Hypertriglyceridemia

ClinicalTrials.gov record

Registration

Registration: NCT06555640
Study type: INTERVENTIONAL
Allocation: RANDOMIZED
Phase: PHASE2
Masking: QUADRUPLE
Status: COMPLETED
Enrollment: 79
Start: 2024-08-01
Primary completion: 2025-06-30
Lead sponsor: Zhejiang Doer Biologics Co., Ltd.
Conditions: Severe Hypertriglyceridemia
Interventions: DRUG:DR10624 Injection; DRUG:Placebo
Results posted: FALSE

Registered primary outcomes

Change of fasting TG [From baseline to Week 12]

Linked records (0)

Automatic links, confirmed or rejected during screening. A record citing this registration may be a secondary analysis, a commentary or a review that mentions the trial.

No records link to this registration yet.